{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T17:13:35Z","timestamp":1793726015392,"version":"4.6.1"},"reference-count":43,"publisher":"Wiley","issue":"7","license":[{"start":{"date-parts":[[2022,4,25]],"date-time":"2022-04-25T00:00:00Z","timestamp":1650844800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100014091","name":"AstraZeneca Pharma Poland","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100014091","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["dom-pubs.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Diabetes Obesity Metabolism"],"published-print":{"date-parts":[[2022,7]]},"abstract":"Abstract<\/jats:title>\n \n Aim<\/jats:title>\n To assess the efficacy, safety and tolerability of cotadutide in patients with type 2 diabetes mellitus and chronic kidney disease.<\/jats:p>\n <\/jats:sec>\n \n Materials and Methods<\/jats:title>\n \n In this phase 2a study (NCT03550378), patients with body mass index 25\u201045\u2009kg\/m\n 2<\/jats:sup>\n , estimated glomerular filtration rate 30\u201059\u2009ml\/min\/1.73\u2009m\n 2<\/jats:sup>\n and type 2 diabetes [glycated haemoglobin 6.5\u201010.5% (48\u201091\u2009mmol\/mol)] controlled with insulin and\/or oral therapy combination, were randomized 1:1 to once\u2010daily subcutaneous cotadutide (50\u2010300\u2009\u03bcg) or placebo for 32\u2009days. The primary endpoint was plasma glucose concentration assessed using a mixed\u2010meal tolerance test.\n <\/jats:p>\n <\/jats:sec>\n \n Results<\/jats:title>\n \n Participants receiving cotadutide (n\u00a0=\u00a021) had significant reductions in the mixed\u2010meal tolerance test area under the glucose concentration\u2010time curve (\u201326.71% vs. +3.68%,\n p<\/jats:italic>\n \u2009<\u2009.001), more time in target glucose range on continuous glucose monitoring (+14.79% vs. \u201321.23%,\n p<\/jats:italic>\n \u00a0=\u00a0.001) and significant reductions in absolute bodyweight (\u20133.41\u2009kg vs. \u20130.13\u2009kg,\n p<\/jats:italic>\n \u2009<\u2009.001) versus placebo (n\u00a0=\u00a020). In patients with baseline micro\u2010 or macroalbuminuria (n\u00a0=\u00a018), urinary albumin\u2010to\u2010creatinine ratios decreased by 51% at day 32 with cotadutide versus placebo (\n p<\/jats:italic>\n \u00a0=\u00a0.0504). No statistically significant difference was observed in mean change in estimated glomerular filtration rate between treatments. Mild\/moderate adverse events occurred in 71.4% of participants receiving cotadutide and 35.0% receiving placebo.\n <\/jats:p>\n <\/jats:sec>\n \n Conclusions<\/jats:title>\n We established the efficacy of cotadutide in this patient population, with significantly improved postprandial glucose control and reduced bodyweight versus placebo. Reductions in urinary albumin\u2010to\u2010creatinine ratios suggest potential benefits of cotadutide on kidney function, supporting further evaluation in larger, longer\u2010term clinical trials.<\/jats:p>\n <\/jats:sec>","DOI":"10.1111\/dom.14712","type":"journal-article","created":{"date-parts":[[2022,4,11]],"date-time":"2022-04-11T08:12:36Z","timestamp":1649664756000},"page":"1360-1369","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":78,"title":["Efficacy and safety of cotadutide, a dual glucagon\u2010like peptide\u20101 and glucagon receptor agonist, in a randomized phase 2a study of patients with type 2 diabetes and chronic kidney disease"],"prefix":"10.1111","volume":"24","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2706-2669","authenticated-orcid":false,"given":"Victoria E. R.","family":"Parker","sequence":"first","affiliation":[{"name":"Research and Early Development, Cardiovascular, Renal and Metabolism, BioPharmaceuticals R&D AstraZeneca Cambridge UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thuong","family":"Hoang","sequence":"additional","affiliation":[{"name":"GW Pharmaceuticals Cambridge UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heike","family":"Schlichthaar","sequence":"additional","affiliation":[{"name":"Study Center, SMO.MD GmbH Magdeburg Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fraser W.","family":"Gibb","sequence":"additional","affiliation":[{"name":"Royal Infirmary of Edinburgh Edinburgh UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barbara","family":"Wenzel","sequence":"additional","affiliation":[{"name":"APEX GmbH Munich Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maximillian G.","family":"Posch","sequence":"additional","affiliation":[{"name":"Charite Research Organisation GmbH Berlin Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ludger","family":"Rose","sequence":"additional","affiliation":[{"name":"Zentrum fur Diabetes M\u00fcnster Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi\u2010Ting","family":"Chang","sequence":"additional","affiliation":[{"name":"Early Clinical Development, Research and Early Development, Cardiovascular, Renal and Metabolism (CVRM), BioPharmaceuticals R&D AstraZeneca Gaithersburg MD USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcella","family":"Petrone","sequence":"additional","affiliation":[{"name":"Clinical Pharmacology and Safety Sciences AstraZeneca Cambridge UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lars","family":"Hansen","sequence":"additional","affiliation":[{"name":"Early Clinical Development, Research and Early Development, Cardiovascular, Renal and Metabolism (CVRM), BioPharmaceuticals R&D AstraZeneca Gaithersburg MD USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2978-1886","authenticated-orcid":false,"given":"Philip","family":"Ambery","sequence":"additional","affiliation":[{"name":"Late Clinical Development, Cardiovascular, Renal and Metabolism, BioPharmaceuticals R&D AstraZeneca Gothenburg Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lutz","family":"Jermutus","sequence":"additional","affiliation":[{"name":"Research and Early Development, Cardiovascular, Renal and Metabolism, BioPharmaceuticals R&D AstraZeneca Cambridge UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3126-3730","authenticated-orcid":false,"given":"Hiddo J. L.","family":"Heerspink","sequence":"additional","affiliation":[{"name":"Department of Clinical Pharmacy and Pharmacology University of Groningen Groningen The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3957-1981","authenticated-orcid":false,"given":"Rory J.","family":"McCrimmon","sequence":"additional","affiliation":[{"name":"School of Medicine, Ninewells Hospital University of Dundee Dundee UK"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2022,4,25]]},"reference":[{"key":"e_1_2_9_2_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.mcna.2012.10.001"},{"key":"e_1_2_9_3_1","doi-asserted-by":"publisher","DOI":"10.3390\/jcm9040947"},{"key":"e_1_2_9_4_1","doi-asserted-by":"publisher","DOI":"10.1177\/2054358117698669"},{"key":"e_1_2_9_5_1","doi-asserted-by":"publisher","DOI":"10.1159\/000504558"},{"issue":"1","key":"e_1_2_9_6_1","first-page":"49","article-title":"Diabetic kidney disease: world wide difference of prevalence and risk factors","volume":"5","author":"Gheith O","year":"2016","journal-title":"J Nephropharmacol"},{"key":"e_1_2_9_7_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1523-1755.2003.00712.x"},{"key":"e_1_2_9_8_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-8587(18)30051-2"},{"key":"e_1_2_9_9_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.1001680"},{"key":"e_1_2_9_10_1","doi-asserted-by":"publisher","DOI":"10.2337\/dc15-1182"},{"key":"e_1_2_9_11_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2020.01.013"},{"key":"e_1_2_9_12_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.metabol.2020.154433"},{"key":"e_1_2_9_13_1","doi-asserted-by":"publisher","DOI":"10.2337\/dc14-1296"},{"key":"e_1_2_9_14_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1811744"},{"key":"e_1_2_9_15_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2024816"},{"key":"e_1_2_9_16_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00125-018-4729-5"},{"issue":"22","key":"e_1_2_9_17_1","first-page":"2197","article-title":"Liraglutide and renal outcomes in type 2 diabetes","volume":"377","author":"Mann JFE","year":"2017","journal-title":"N Engl J Med"},{"key":"e_1_2_9_18_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1607141"},{"key":"e_1_2_9_19_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2015.08.038"},{"key":"e_1_2_9_20_1","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2020.00967"},{"key":"e_1_2_9_21_1","doi-asserted-by":"publisher","DOI":"10.1111\/dom.12735"},{"key":"e_1_2_9_22_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(18)30726-8"},{"key":"e_1_2_9_23_1","doi-asserted-by":"publisher","DOI":"10.1038\/s42255-020-0209-6"},{"key":"e_1_2_9_24_1","doi-asserted-by":"publisher","DOI":"10.2337\/dc20-2151"},{"key":"e_1_2_9_25_1","doi-asserted-by":"crossref","unstructured":"ParkerV RobertsonD HansenL et al.Cotadutide (MEDI0382) a dual receptor agonist with balanced glucagon\u2010like peptide\u20101 and glucagon activity modulates hepatic glycogen stores. Presented at: European Association for the Study of Diabetes 55th Annual Meeting; September 18 2019;Barcelona Spain.","DOI":"10.2337\/db20-354-OR"},{"key":"e_1_2_9_26_1","doi-asserted-by":"publisher","DOI":"10.1152\/ajprenal.00560.2015"},{"key":"e_1_2_9_27_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.molmet.2020.101102"},{"key":"e_1_2_9_28_1","doi-asserted-by":"publisher","DOI":"10.1093\/ajhp\/62.2.173"},{"key":"e_1_2_9_29_1","doi-asserted-by":"publisher","DOI":"10.1210\/clinem\/dgz047"},{"key":"e_1_2_9_30_1","doi-asserted-by":"publisher","DOI":"10.2215\/CJN.11881019"},{"key":"e_1_2_9_31_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-8587(17)30013-X"},{"key":"e_1_2_9_32_1","doi-asserted-by":"publisher","DOI":"10.2337\/dc20-1622"},{"key":"e_1_2_9_33_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-8587(20)30313-2"},{"key":"e_1_2_9_34_1","doi-asserted-by":"publisher","DOI":"10.2147\/IJGM.S285191"},{"key":"e_1_2_9_35_1","doi-asserted-by":"publisher","DOI":"10.1177\/2042018819865398"},{"key":"e_1_2_9_36_1","doi-asserted-by":"publisher","DOI":"10.1152\/ajprenal.00527.2014"},{"key":"e_1_2_9_37_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.regpep.2006.12.016"},{"key":"e_1_2_9_38_1","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1908706116"},{"key":"e_1_2_9_39_1","doi-asserted-by":"publisher","DOI":"10.1111\/dom.12601"},{"key":"e_1_2_9_40_1","doi-asserted-by":"publisher","DOI":"10.1152\/ajprenal.00579.2019"},{"key":"e_1_2_9_41_1","doi-asserted-by":"publisher","DOI":"10.1055\/s-0042-101794"},{"key":"e_1_2_9_42_1","doi-asserted-by":"publisher","DOI":"10.1155\/2010\/231832"},{"key":"e_1_2_9_43_1","doi-asserted-by":"publisher","DOI":"10.1093\/ndt\/5.2.110"},{"issue":"3","key":"e_1_2_9_44_1","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/S0031-6997(25)06576-7","article-title":"Glucagon and the circulation","volume":"35","author":"Farah AE","year":"1983","journal-title":"Pharmacol Rev"}],"container-title":["Diabetes, Obesity and Metabolism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/dom.14712","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/dom.14712","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/dom-pubs.pericles-prod.literatumonline.com\/doi\/pdf\/10.1111\/dom.14712","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T22:53:10Z","timestamp":1761864790000},"score":1,"resource":{"primary":{"URL":"https:\/\/dom-pubs.pericles-prod.literatumonline.com\/doi\/10.1111\/dom.14712"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,4,25]]},"references-count":43,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2022,7]]}},"alternative-id":["10.1111\/dom.14712"],"URL":"https:\/\/doi.org\/10.1111\/dom.14712","archive":["Portico"],"relation":{"has-review":[{"id-type":"doi","id":"10.1111\/DOM.14712\/v2\/review2","asserted-by":"object"},{"id-type":"doi","id":"10.1111\/DOM.14712\/v2\/review1","asserted-by":"object"},{"id-type":"doi","id":"10.1111\/DOM.14712\/v1\/decision1","asserted-by":"object"},{"id-type":"doi","id":"10.1111\/DOM.14712\/v2\/response1","asserted-by":"object"},{"id-type":"doi","id":"10.1111\/DOM.14712\/v1\/review1","asserted-by":"object"},{"id-type":"doi","id":"10.1111\/DOM.14712\/v1\/review2","asserted-by":"object"},{"id-type":"doi","id":"10.1111\/DOM.14712\/v1\/review3","asserted-by":"object"},{"id-type":"doi","id":"10.1111\/DOM.14712\/v1\/review4","asserted-by":"object"},{"id-type":"doi","id":"10.1111\/DOM.14712\/v2\/decision1","asserted-by":"object"}]},"ISSN":["1462-8902","1463-1326"],"issn-type":[{"value":"1462-8902","type":"print"},{"value":"1463-1326","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,4,25]]},"assertion":[{"value":"2022-01-27","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-04-04","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-04-25","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}